Di Paolo, Daniela <br/><br/>
New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.  [electronic resource] 

 -  Oncotarget  Oct 2015 
 - 28774-89 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.4342  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anaplastic Lymphoma Kinase<br/>Animals<br/>Antineoplastic Agents--pharmacokinetics<br/>Biological Availability<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Combined Modality Therapy<br/>Dose-Response Relationship, Drug<br/>Female<br/>Gene Expression Regulation, Enzymologic--drug effects<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Half-Life<br/>Humans<br/>Liposomes<br/>Male<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Molecular Targeted Therapy<br/>Mutation<br/>Nanoparticles<br/>Neuroblastoma--enzymology<br/>Protein Kinase Inhibitors--pharmacokinetics<br/>RNA Interference<br/>RNA, Small Interfering--genetics<br/>RNAi Therapeutics<br/>Receptor Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Transfection<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays